PE20110999A1 - Compuestos derivados de 6-piperazin-1-il-9h-purina - Google Patents

Compuestos derivados de 6-piperazin-1-il-9h-purina

Info

Publication number
PE20110999A1
PE20110999A1 PE2011001219A PE2011001219A PE20110999A1 PE 20110999 A1 PE20110999 A1 PE 20110999A1 PE 2011001219 A PE2011001219 A PE 2011001219A PE 2011001219 A PE2011001219 A PE 2011001219A PE 20110999 A1 PE20110999 A1 PE 20110999A1
Authority
PE
Peru
Prior art keywords
methyl
purine
piperazin
compounds derived
tertahydro
Prior art date
Application number
PE2011001219A
Other languages
English (en)
Spanish (es)
Inventor
Peter Charles Astles
Rossella Guidetti
Michael Wade Tidwell
Sean Patrick Hollinshead
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20110999A1 publication Critical patent/PE20110999A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2011001219A 2008-12-18 2009-12-09 Compuestos derivados de 6-piperazin-1-il-9h-purina PE20110999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13858908P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
PE20110999A1 true PE20110999A1 (es) 2012-01-16

Family

ID=41719189

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001219A PE20110999A1 (es) 2008-12-18 2009-12-09 Compuestos derivados de 6-piperazin-1-il-9h-purina

Country Status (29)

Country Link
US (1) US8252798B2 (https=)
EP (1) EP2379555B1 (https=)
JP (1) JP5559812B2 (https=)
KR (1) KR101319630B1 (https=)
CN (1) CN102256977B (https=)
AR (1) AR075104A1 (https=)
AU (1) AU2009335997B2 (https=)
BR (1) BRPI0923195A2 (https=)
CA (1) CA2746740C (https=)
CL (1) CL2011001464A1 (https=)
CO (1) CO6390101A2 (https=)
CR (1) CR20110340A (https=)
DO (1) DOP2011000196A (https=)
EA (1) EA018386B1 (https=)
EC (1) ECSP11011151A (https=)
ES (1) ES2536880T3 (https=)
HN (1) HN2011001700A (https=)
IL (1) IL213167A (https=)
MA (1) MA32904B1 (https=)
MX (1) MX2011006442A (https=)
NZ (1) NZ593088A (https=)
PA (1) PA8851501A1 (https=)
PE (1) PE20110999A1 (https=)
SG (1) SG172253A1 (https=)
TN (1) TN2011000291A1 (https=)
TW (1) TWI376378B (https=)
UA (1) UA104010C2 (https=)
WO (1) WO2010080306A1 (https=)
ZA (1) ZA201103943B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
IN2012DN02474A (https=) 2009-08-28 2015-08-21 Arena Pharm Inc
US20130096104A1 (en) * 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
AR080711A1 (es) 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
BR112012024587A2 (pt) * 2010-03-31 2016-05-31 Lilly Co Eli compostos de purina usados como agonistas de cb2
TW201217387A (en) 2010-09-15 2012-05-01 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use
BR112013011520A2 (pt) 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
AU2012222149B2 (en) 2011-02-25 2017-06-29 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP2678330A1 (en) 2011-02-25 2014-01-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
CN103827115A (zh) * 2011-09-20 2014-05-28 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶化合物、组合物和使用方法
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
CN104903316B (zh) * 2012-08-16 2017-11-28 詹森药业有限公司 作为n型钙通道阻滞剂的取代的吡唑
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
HUE035333T2 (en) * 2013-05-02 2018-05-02 Hoffmann La Roche Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017052394A1 (en) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2018137176A1 (en) * 2017-01-25 2018-08-02 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2017184412A1 (en) 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis
CA3036382A1 (en) * 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
US20200078358A1 (en) 2017-05-08 2020-03-12 Arena Pharmaceuticals, Inc. Compounds and Methods for Treatment of Visceral Pain
WO2024017227A1 (zh) * 2022-07-21 2024-01-25 长春金赛药业有限责任公司 取代的稠环大麻素受体化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
KR20070054737A (ko) * 2004-10-22 2007-05-29 화이자 프로덕츠 인코포레이티드 퓨린 화합물의 제조 방법
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
KR101450535B1 (ko) * 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 E1 활성화 효소의 억제제
US20120295915A1 (en) * 2009-11-24 2012-11-22 Chaudhari Amita M Azabenzimidazoles as fatty acid synthase inhibitors
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Also Published As

Publication number Publication date
SG172253A1 (en) 2011-07-28
DOP2011000196A (es) 2011-10-31
IL213167A (en) 2013-11-28
TN2011000291A1 (en) 2012-12-17
ZA201103943B (en) 2012-11-28
CN102256977B (zh) 2014-04-16
CO6390101A2 (es) 2012-02-29
KR20110084459A (ko) 2011-07-22
ECSP11011151A (es) 2011-07-29
CA2746740A1 (en) 2010-07-15
JP2012512873A (ja) 2012-06-07
ES2536880T3 (es) 2015-05-29
CN102256977A (zh) 2011-11-23
CR20110340A (es) 2011-09-16
AU2009335997A1 (en) 2011-06-23
KR101319630B1 (ko) 2013-10-17
MX2011006442A (es) 2011-07-19
US8252798B2 (en) 2012-08-28
EA201170832A1 (ru) 2011-12-30
HN2011001700A (es) 2013-05-06
CL2011001464A1 (es) 2012-01-20
EP2379555A1 (en) 2011-10-26
JP5559812B2 (ja) 2014-07-23
PA8851501A1 (es) 2010-07-27
WO2010080306A1 (en) 2010-07-15
IL213167A0 (en) 2011-07-31
BRPI0923195A2 (pt) 2016-02-16
EP2379555B1 (en) 2015-02-25
NZ593088A (en) 2012-12-21
AU2009335997B2 (en) 2012-05-10
AR075104A1 (es) 2011-03-09
EA018386B1 (ru) 2013-07-30
MA32904B1 (fr) 2011-12-01
TWI376378B (en) 2012-11-11
UA104010C2 (en) 2013-12-25
US20100160288A1 (en) 2010-06-24
TW201024296A (en) 2010-07-01
CA2746740C (en) 2014-01-14

Similar Documents

Publication Publication Date Title
PE20110999A1 (es) Compuestos derivados de 6-piperazin-1-il-9h-purina
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
PE20151064A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CR10874A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3 metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro benzonitrilo y metodos para el uso de los mismos
PE20080931A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20110403A1 (es) Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer
PE20121048A1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CO6251282A2 (es) Oxazolidinonas sustituidas y su uso
ECSP099751A (es) Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazo[4,5-b]piridin-5-amina y su uso para el tratamiento del cáncer
PE20151084A1 (es) Derivados de pirimidinona inhibidoras de la elastasa de neutrofilos humanos (hne)
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
PE20121276A1 (es) Compuestos espirociclicos que contienen nitrogeno y su uso medicinal
PE20211290A1 (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson
CY1115866T1 (el) Τριαζολοπυριμιδινες
PE20091306A1 (es) Pirrolopirimidinas y pirrolopiridinas
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20080527A1 (es) Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k)
PE20090361A1 (es) Acidos benzoilamino-indan-2-carboxilicos sustituidos como inhibidores de cxcr5
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
AR071833A1 (es) Inhibidores de quinasas (limk2), composiciones que los comprenden y metodos para tratar o prevenir enfermedades
PE20180116A1 (es) HETEROCICLILMETIL-TIENOURACILO COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2b
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
CL2016000495A1 (es) Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades.
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
PE20170445A1 (es) Compuestos biciclicos sustituidos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed